Lung-Targeted Exosome Modification Service
- Non-small cell lung cancer (NSCLC) targeted therapies
- Pulmonary fibrosis treatment
- Chronic obstructive pulmonary disease (COPD) and asthma therapies
- Lung infections, including pneumonia
- Acute lung injury and respiratory distress syndrome
- Delivered as a frozen solution or lyophilized powder, depending on the specific process and client requirements
- Accompanied by batch number, production date, storage temperature, and other basic information
- Information on the origin of the exosomes, purification process, and key quality control points
- Lung-targeting modification methods and modification efficiency
- Comprehensive characterization data and analysis results (e.g., particle size distribution, protein profiling, morphological observations, etc.)
- Functional validation experiment results (cellular uptake efficiency, in vivo/in vitro tracking, etc.)
- Quality control and safety assessment information
- MtoZ Biolabs can provide necessary technical support and consultation if any issues arise during follow-up research or preclinical studies
- Should you require further scale-up or batch production of lung-targeted exosomes, we can also offer industrial-scale technical consulting and process design
Exosomes are extracellular vesicles measuring approximately 30-150 nm in diameter, secreted by various cell types. They play critical roles in intercellular communication by delivering bioactive molecules such as microRNAs, proteins, and lipids. Due to their natural origin, stability, and low immunogenicity, exosomes have gained widespread attention as drug delivery vehicles. Specifically, targeting exosomes to lung tissue offers significant therapeutic benefits for pulmonary diseases, including enhanced treatment efficacy, reduced systemic side effects, and improved retention and bioavailability within lung tissue. To achieve lung-specific delivery, advanced modification techniques can be employed, such as lung-specific peptide screening via phage display technology, ligand conjugation, antibody modification, genetic engineering, and membrane fusion.
MtoZ Biolabs provides a Lung-Targeted Exosome Modification Service utilizing cutting-edge technological platforms, including phage display for screening lung-specific peptides, to effectively achieve targeted pulmonary delivery of exosomes. Our customized exosome modification services precisely deliver therapeutic molecules such as microRNAs or proteins into lung cells, enhancing therapeutic outcomes for various pulmonary conditions.
Analysis Workflow
1. Exosome Isolation and Purification
Isolation of high-quality exosomes from selected cells or biological fluids using ultracentrifugation, size-exclusion chromatography (SEC), and ultrafiltration methods.
2. Lung-Targeting Peptide Screening and Design
Identification and selection of lung-specific targeting peptides through phage display technology to enhance exosome uptake and retention in lung tissue.
3. Exosome Modification and Functionalization
Covalent conjugation or genetic engineering of selected peptides onto exosome surfaces, significantly enhancing lung-targeted delivery efficiency.
4. Validation and Characterization
Comprehensive characterization of modified exosomes using electron microscopy, nanoparticle tracking analysis (NTA), Western blotting, flow cytometry, and cellular uptake assays to confirm targeting efficiency and functional integrity.
Zeng, H. et al. Cells. 2023.
Figure 1. Strategies for Targeting Exosomes to Tissues in vivo
Service Advantages
1. Efficient Lung Targeting: Precise delivery to lung tissues through targeted peptides, greatly improving therapeutic targeting.
2. Advanced Screening Techniques: Accurate selection of lung-specific peptides via phage display technology.
3. Rigorous Validation Processes: Robust validation protocols to ensure high efficiency, purity, and stability of exosomes.
4. Customized Service Solutions: Personalized modification strategies tailored to meet specific therapeutic and research needs.
Applications
Case Study
1. Docetaxel-Loaded Exosomes for Targeting Non-Small Cell Lung Cancer: Preparation and Evaluation in vitro and in vivo
This study investigates the preparation and evaluation of Docetaxel (DTX)-loaded exosomes (EXO-DTX) for targeting non-small cell lung cancer (NSCLC). Exosomes were isolated from A549 cancer cells and characterized using TEM, NTA, and Western blot. The DTX payload was encapsulated using electroporation, and in vitro evaluations showed EXO-DTX had significantly higher cytotoxicity, enhanced cellular uptake, and better tumor targeting compared to free DTX. In vivo results demonstrated improved targeting to tumor tissue. This study highlights the potential of tumor-derived exosomes as a drug delivery system for NSCLC treatment. Lung-targeted exosome modification services utilize advanced technologies to enhance drug delivery to lung tissues. By modifying exosomes with specific targeting molecules, we can improve the efficacy and precision of treatments. This service can provide personalized solutions to enhance the therapeutic effects of anticancer agents and other drugs in lung diseases, including lung cancer.
Wang, Y. et al. Drug Deliv. 2021.
Figure 2. Characterization of the Exosome and EXO-DTX
Deliverables
1. Modified Exosome Formulation (Final Product)
2. Detailed Technical or Summary Report
3. Technical Support and Ongoing Consultation Services
MtoZ Biolabs is dedicated to advancing precision medicine in pulmonary diseases through sophisticated exosome modification technologies. Our Lung-Targeted Exosome Modification Service provides researchers and clinicians with precise, efficient pulmonary drug delivery tools, strongly supporting innovative treatments and improved patient outcomes in respiratory diseases.
How to order?
